Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACALABRUTINIB vs CALQUENCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.
Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy,Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
FDA-approved: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,FDA-approved: Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),Off-label: Treatment of Waldenström macroglobulinemia,Off-label: Treatment of marginal zone lymphoma
100 mg orally every 12 hours.
100 mg orally twice daily.
Terminal elimination half-life is approximately 1 hour. Clinical context: short half-life supports twice-daily dosing, but BTK occupancy remains >90% over 12 hours due to irreversible binding.
Terminal elimination half-life is 8 hours at steady state, supporting twice-daily dosing.
Primarily metabolized by CYP3A4, with minor contributions from CYP2C8 and glutathione conjugation.
Primarily metabolized by CYP3A4 to form acalabrutinib M27 (active metabolite). Minor routes include glutathione conjugation and hydrolysis. Acalabrutinib is also a substrate of CYP3A5 and to a lesser extent CYP2C8.
Primarily hepatic metabolism (CYP3A4); fecal excretion accounts for approximately 86% (including 69% as metabolites, 17% as unchanged drug). Renal excretion is minimal (<1% unchanged).
Fecal (77%), renal (15% as unchanged drug and metabolites).
97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
97% bound to plasma proteins (albumin and alpha-1 acid glycoprotein).
Approximately 34 L (approx. 0.5 L/kg for a 70 kg adult), indicating moderate distribution into tissues.
Approximately 10 L/kg, indicating extensive tissue distribution.
Oral bioavailability: approximately 70–75% (absolute bioavailability not determined in humans; estimate based on mass balance and exposure data).
Oral bioavailability is approximately 70%; absorption is unaffected by food.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg orally once daily.
No dose adjustment required for Cr Cl >=30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg once daily.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 100 mg orally once daily. Child-Pugh C: Avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 100 mg once daily. Child-Pugh C: avoid use.
Not approved for patients <18 years; safety and efficacy not established.
Not established for pediatric patients.
No specific dose adjustment; monitor for toxicity, especially infections and bleeding.
No specific dose adjustment beyond standard monitoring for toxicity.
No boxed warning is included in the FDA-approved prescribing information.
None
Hemorrhage: Fatal bleeding events have occurred; monitor for bleeding and manage appropriately,Infections: Serious infections (including opportunistic infections) have occurred; consider prophylaxis,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia; monitor blood counts,Second primary malignancies: Including skin cancers; advise sun protection,Atrial fibrillation and flutter: Monitor for cardiac arrhythmias,Hepatotoxicity: Elevations of liver enzymes; monitor hepatic function
Hemorrhage: Fatal and serious bleeding events have occurred. Monitor for signs of bleeding, especially in patients on antithrombotic agents or with thrombocytopenia. Consider benefit-risk of holding acalabrutinib for 3-7 days pre- and post-surgery.,Infections: Fatal and serious infections, including opportunistic infections, have occurred. Monitor for signs and symptoms of infection and treat promptly.,Cytopenias: Grade 3 or 4 cytopenias (neutropenia, anemia, thrombocytopenia) can occur. Monitor complete blood counts regularly.,Second primary malignancies: Including skin cancers and other solid tumors. Advise patients to use sun protection.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for cardiac arrhythmias and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have occurred. Monitor liver function tests.,Interstitial lung disease (ILD): Cases of ILD/pneumonitis have occurred. Monitor for pulmonary symptoms and manage as indicated.
None
None (no absolute contraindications). Avoid use in patients with severe hepatic impairment (Child-Pugh class C) due to lack of data; use with caution in moderate impairment (Child-Pugh class B).
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition increasing acalabrutinib exposure. No other significant food interactions.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit (which contain strong CYP3A4 inhibitors) during treatment with CALQUENCE. No other specific food restrictions are required. The drug can be taken with or without food.
Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, no adequate data; however, based on mechanism and animal findings, there is potential risk of teratogenicity, especially during first trimester. Use during pregnancy should be avoided unless maternal benefit outweighs fetal risk.
Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of acalabrutinib to pregnant rats during organogenesis resulted in embryofetal mortality and malformations at exposures below the clinical exposure at the recommended human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester exposure poses highest risk; second and third trimesters also carry risk of fetal toxicity.
No data on acalabrutinib in human milk. Based on molecular weight and pharmacokinetics, excretion into breast milk is likely. M/P ratio unknown. Because of potential serious adverse reactions in breastfed infants, advise not to breastfeed during treatment and for 2 weeks after last dose.
No data are available on the presence of acalabrutinib or its metabolites in human milk, effects on the breastfed child, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with CALQUENCE and for at least 2 weeks after the last dose. M/P ratio is unknown.
No established dosing adjustments for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may affect exposure; however, no specific dose recommendations are available. If used, therapeutic drug monitoring is not established; close clinical monitoring for efficacy and toxicity is advised.
No specific dose adjustments are recommended for pregnancy due to lack of data on pharmacokinetic changes. However, because of potential alterations in drug metabolism and clearance during pregnancy, therapeutic drug monitoring may be considered if available. The manufacturer does not provide guidance for dose adjustment in pregnant women; use during pregnancy should be avoided unless clearly needed.
Monitor for bleeding, especially if on antiplatelet or anticoagulant therapy. Acalabrutinib is a selective BTK inhibitor with minimal off-target effects compared to ibrutinib, but still carries risks of atrial fibrillation, hypertension, and infections. Start with 100 mg twice daily until progression or unacceptable toxicity. Administer with a full glass of water; do not open capsules. Consider dose reduction for severe hepatic impairment (Child-Pugh C).
CALQUENCE (acalabrutinib) is a selective BTK inhibitor used in B-cell malignancies. It has fewer off-target effects than ibrutinib, particularly less atrial fibrillation and bleeding. Monitor for atrial fibrillation, hypertension, infections (especially respiratory), and bleeding events. Drug interactions with CYP3A4 inducers/inhibitors are significant; avoid concurrent use with strong CYP3A4 inhibitors or inducers. May need to hold for 3 days before and after procedures due to bleeding risk. Consider antiviral prophylaxis for herpes zoster in high-risk patients. Do not crush or break capsules; swallow whole with water. Dose adjustment for severe hepatic impairment (Child-Pugh C) is required.
Take exactly as prescribed, twice daily about 12 hours apart.,Swallow capsules whole with water; do not crush or chew.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any signs of bleeding (unusual bruising, black/tarry stools, blood in urine) or infection (fever, chills) immediately.,Use effective contraception during treatment and for at least 1 week after last dose.,Do not stop or change dose without consulting your doctor.,Wash hands frequently and avoid crowds to reduce infection risk.
Take CALQUENCE exactly as prescribed, usually twice daily with or without food. Swallow capsules whole; do not open, break, or chew them.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while taking this medication, as they can affect how the drug works.,Tell your healthcare provider about all medications you take, including prescription, over-the-counter, vitamins, and herbal products, especially St. John's wort.,CALQUENCE can increase your risk of serious infections, bleeding problems, and heart rhythm issues. Report any signs of infection (fever, chills), unusual bruising or bleeding, palpitations, or dizziness.,Do not stop taking CALQUENCE without consulting your healthcare provider. If you miss a dose, take it as soon as you remember unless it is less than 6 hours until your next dose; then skip the missed dose.,Women who are pregnant or breastfeeding should not take CALQUENCE. Effective contraception is needed during treatment and for 1 week after the last dose.,Keep CALQUENCE in the original container at room temperature (68°F to 77°F), away from moisture and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACALABRUTINIB vs CALQUENCE, answered by our medical review team.
ACALABRUTINIB is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.. CALQUENCE is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACALABRUTINIB and CALQUENCE depend on the specific clinical indication. These are both BTK Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACALABRUTINIB is: 100 mg orally every 12 hours.. The standard adult dose of CALQUENCE is: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACALABRUTINIB and CALQUENCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACALABRUTINIB is classified as Category C. Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, . CALQUENCE is classified as Category C. Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.